Fierce Biotech1 min read
saveLilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
Eli Lilly has added another myelofibrosis prospect to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech Calytrix Bio.
comments(0)
5-min edit window · permanent after that